KPIs & Operating Metrics(New)
Advance Purchase Agreements (Apas)Breakdown Of AssetsCollabration Revenue By CategoryCollabration Revenue By Category AnnualCost Of SalesDeferred Revenue By SegmentDoses DeliveredEmployee StatisticsGrant Revenue By Category AnnualGrant Revenue By CategoyGross Margin %Gross ProfitIncome (Loss) Before Income Tax By RegionManufacturing Technology Center (Mtc)Operating Expense As A % Of Total Revenue %Operating Expense SegregationProduct Revenue By Geography %Product Revenue By Geography Annual %Product Sales By GeographyProduct Sales By Geography AnnualProfitabilityProfitability %Profitability AnnualProfitability Annual %Property And Equipment BreakdownProperty And Equipment By GeographyPurchase CommitmentsRemaining Performance ObligationRemaining Performance ObligationsRevenue By Major CustomersRevenue By Major Customers %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Total Contractual Obligations AnnualTotal Deferred Revenue
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Gross Profit (2020 - 2025)

Moderna (MRNA) has disclosed Gross Profit for 6 consecutive years, with $226.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Gross Profit fell 47.32% to $226.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 billion, a 43.64% decrease, with the full-year FY2025 number at $1.1 billion, down 39.28% from a year prior.
  • Gross Profit was $226.0 million for Q4 2025 at Moderna, down from $809.0 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $6.3 billion in Q4 2021 to a low of -$410.0 million in Q3 2023.
  • A 5-year average of $1.7 billion and a median of $1.2 billion in 2023 define the central range for Gross Profit.
  • Peak YoY movement for Gross Profit: surged 21700.0% in 2021, then tumbled 118.11% in 2023.
  • Moderna's Gross Profit stood at $6.3 billion in 2021, then tumbled by 49.42% to $3.2 billion in 2022, then crashed by 40.56% to $1.9 billion in 2023, then plummeted by 77.21% to $429.0 million in 2024, then crashed by 47.32% to $226.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Gross Profit are $226.0 million (Q4 2025), $809.0 million (Q3 2025), and $23.0 million (Q2 2025).